Farber Xintian
About Farber Xintian
Farber Xintian CRO company engaged in clinical services of radionuclide drugs. The company focuses on the field of nuclide drugs. Through cooperation with domestic experts in the field of nuclide drugs, the company introduces IP and relies on its own resource advantages to create a VIC model for domestic nuclide drugs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $43.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2024)
Industries & Categories
Medical, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/farber-xintian-147306 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.